HC Wainwright Issues Positive Forecast for Liquidia Earnings

Liquidia Co. (NASDAQ:LQDA) – Investment analysts at HC Wainwright raised their FY2024 earnings per share (EPS) estimates for shares of Liquidia in a research report issued on Thursday, November 14th. HC Wainwright analyst A. Fein now anticipates that the company will earn ($1.51) per share for the year, up from their previous forecast of ($1.54). HC Wainwright has a “Buy” rating and a $29.00 price target on the stock. The consensus estimate for Liquidia’s current full-year earnings is ($1.55) per share. HC Wainwright also issued estimates for Liquidia’s FY2025 earnings at ($1.62) EPS and FY2028 earnings at ($0.16) EPS.

Several other analysts have also recently commented on LQDA. Bank of America decreased their price objective on shares of Liquidia from $24.00 to $23.00 and set a “buy” rating for the company in a research note on Tuesday, August 20th. BTIG Research cut their price objective on shares of Liquidia from $29.00 to $25.00 and set a “buy” rating on the stock in a research note on Monday, August 19th. Raymond James upgraded shares of Liquidia from an “outperform” rating to a “strong-buy” rating in a research note on Monday, August 19th. Needham & Company LLC reiterated a “buy” rating and issued a $19.00 price objective on shares of Liquidia in a research note on Thursday. Finally, Lifesci Capital initiated coverage on shares of Liquidia in a research note on Thursday, October 3rd. They issued an “outperform” rating and a $30.00 price objective on the stock. One analyst has rated the stock with a sell rating, one has given a hold rating, six have given a buy rating and two have assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $24.00.

Liquidia Price Performance

Shares of LQDA stock opened at $9.84 on Monday. The business has a fifty day moving average of $10.52 and a 200 day moving average of $11.48. Liquidia has a 1 year low of $6.10 and a 1 year high of $16.99. The firm has a market capitalization of $832.86 million, a price-to-earnings ratio of -6.04 and a beta of 0.21.

Institutional Trading of Liquidia

Several institutional investors and hedge funds have recently bought and sold shares of the business. Patient Square Capital LP purchased a new stake in Liquidia in the 1st quarter valued at $105,942,000. Vanguard Group Inc. raised its position in Liquidia by 1.5% in the 1st quarter. Vanguard Group Inc. now owns 2,887,274 shares of the company’s stock valued at $42,587,000 after purchasing an additional 43,352 shares during the last quarter. Farallon Capital Management LLC purchased a new stake in Liquidia in the 1st quarter valued at $30,311,000. Whitefort Capital Management LP raised its position in Liquidia by 119.8% in the 3rd quarter. Whitefort Capital Management LP now owns 1,702,025 shares of the company’s stock valued at $17,020,000 after purchasing an additional 927,546 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. raised its position in Liquidia by 144.8% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 390,257 shares of the company’s stock valued at $3,903,000 after purchasing an additional 230,820 shares during the last quarter. Hedge funds and other institutional investors own 64.54% of the company’s stock.

Insider Activity at Liquidia

In related news, CEO Roger Jeffs sold 8,053 shares of Liquidia stock in a transaction that occurred on Monday, October 14th. The shares were sold at an average price of $11.11, for a total value of $89,468.83. Following the completion of the transaction, the chief executive officer now owns 812,193 shares in the company, valued at $9,023,464.23. The trade was a 0.98 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Caligan Partners Lp purchased 150,000 shares of the firm’s stock in a transaction that occurred on Friday, August 30th. The stock was purchased at an average price of $9.51 per share, with a total value of $1,426,500.00. Following the purchase, the director now directly owns 6,994,997 shares of the company’s stock, valued at $66,522,421.47. The trade was a 2.19 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Over the last quarter, insiders sold 21,551 shares of company stock worth $236,021. Corporate insiders own 30.10% of the company’s stock.

About Liquidia

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).